Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

Forouzanfar, 2011, Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis, Lancet, 378, 1461, 10.1016/S0140-6736(11)61351-2 Sotiriou, 2009, Gene-expression signatures in breast cancer, N Engl J Med, 360, 790, 10.1056/NEJMra0801289 Foulkes, 2010, Triple-negative breast cancer, N Engl J Med, 363, 1938, 10.1056/NEJMra1001389 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220 van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 Turner, 2004, Hallmarks of ‘BRCAness’ in sporadic cancers, Nat Rev Cancer, 4, 814, 10.1038/nrc1457 Wilcken, 2008, Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000-2007, Eur J Cancer, 44, 2218, 10.1016/j.ejca.2008.07.019 Loesch, 2002, Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer, J Clin Oncol, 20, 3857, 10.1200/JCO.2002.08.129 Estevez, 2004, Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer, Clin Cancer Res, 10, 3249, 10.1158/1078-0432.CCR-03-0133 Sikov, 2009, Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study, J Clin Oncol, 27, 4693, 10.1200/JCO.2008.21.4163 Chen, 2010, Weekly paclitaxel plus carboplatin is an effective non– anthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer, Ann Oncol, 21, 961, 10.1093/annonc/mdq041 Linderholm, 2009, Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple negative breast cancer, Ann Oncol, 20, 1639, 10.1093/annonc/mdp062 Thomsses, 2012, First-line bevacizumab containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study, Oncology, 82, 218, 10.1159/000336892 Miles, 2013, First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients, Ann Oncol, 24, 2773, 10.1093/annonc/mdt276 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 Brodowicz, 2014, Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses, Br J Cancer, 111, 2051, 10.1038/bjc.2014.504 Clark, 2014, Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis, Core Evid, 9, 1, 10.2147/CE.S52197 Ferrero, 2016, Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: results from the GINECO A-TaXel phase 2 study, Cancer, 122, 3119, 10.1002/cncr.30170 O’Shaughnessy, 2014, Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer, J Clin Oncol, 32, 3840, 10.1200/JCO.2014.55.2984 Zielinski, 2016, Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial, Lancet Oncol, 17, 1230, 10.1016/S1470-2045(16)30154-1 Schneider, 2008, Triple-negative breast cancer: risk factors to potential targets, Clin Cancer Res, 14, 8010, 10.1158/1078-0432.CCR-08-1208 Tutt, 2015, The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) (abstract S3-01), Cancer Res, 75, 10.1158/1538-7445.SABCS14-S3-01 Cameron, 2013, Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial, Lancet Oncol, 14, 933, 10.1016/S1470-2045(13)70335-8 Miller, 2014, Bevacizumab in the adjuvant treatment of HER2 negative breast cancer: final results from Eastern Cooperative Oncology Group E5103 (abstract 500), J Clin Oncol, 32 Yardley, 2017, Nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: results from the randomized phase 2 portion of the TnAcity trial (abstract P5-15-03), Cancer Res, 77, 10.1158/1538-7445.SABCS16-P5-15-03